False Claims Act — Qui Tam Whistleblower Actions Against Government Fraud

The False Claims Act (FCA), 31 U.S.C. §§ 3729–3733, is the federal government's primary civil tool for combating fraud against the government — and one of the most powerful whistleblower statutes in American law. Originally enacted in 1863 (the "Lincoln Law") to address contractor fraud during the Civil War, the FCA imposes civil liability on any person who knowingly submits or causes the submission of a false claim for payment to the federal government, with penalties per false claim plus treble (triple) the government's actual damages. The Act's most distinctive feature is its qui tam provision, which allows private individuals — called "relators" — who know of fraud against the government to file suit on the government's behalf and receive between 15 and 30 percent of the government's recovery. The government may intervene in the suit and take it over, or decline and allow the relator to proceed independently. Since its 1986 amendments significantly strengthened the qui tam mechanism, the FCA has recovered over $75 billion for the federal government — the majority in health care fraud cases involving Medicare and Medicaid billing. The FCA imposes no requirement that the government actually be defrauded; submission of a false claim creates liability even if the government never paid it. The "reverse false claims" provision targets those who improperly avoid paying money owed to the government. The FCA's jurisdictional limits — the public disclosure bar and original source exception — prevent parasitic suits by relators who simply read public disclosures of fraud without providing independent inside knowledge.

Current Law (2026)

Legal Authority

• 31 U.S.C. § 3729 — Imposes liability on any person who knowingly presents a false claim; definitions of "claim," "obligation," and "knowing"; reverse false claims provision (§ 3729(a)(1)(G))
• 31 U.S.C. § 3730 — Civil actions; government's right to intervene; qui tam relator's right to proceed; relator share percentages; anti-retaliation protections; first-to-file rule
• 31 U.S.C. § 3731 — False claims jurisdiction and service; six-year statute of limitations from violation or three years from when government knew or should have known (whichever is later, up to 10 years)
• 31 U.S.C. § 3732 — False claims jurisdiction and venue
• 31 U.S.C. § 3733 — Civil investigative demands; DOJ authority to compel document production before filing suit
• Vermont Agency of Natural Resources v. United States ex rel. Stevens, 529 U.S. 765 (2000) — Relators have Article III standing to file qui tam suits; the government's injury is assigned to the relator by Congress; FCA does not apply to states (states are not "persons" subject to FCA liability)
• United States ex rel. Eisenstein v. City of New York, 556 U.S. 928 (2009) — When the government declines to intervene, it is not a "party" for appellate timing purposes
• Escobar v. Universal Health Services, Inc., 579 U.S. 176 (2016) — Established the "implied false certification" theory: submitting a claim to the government impliedly certifies compliance with material legal conditions of payment; materiality is demanding — only conditions whose violation would cause the government to withhold payment or approval are "material"
• United States ex rel. Polansky v. Executive Health Resources, 599 U.S. 419 (2023) — Government may move to dismiss a qui tam case after declining to intervene, but must first intervene for that purpose; relators do not have absolute veto over dismissal
• United States ex rel. Supervalu Inc. v. United States, 598 U.S. 739 (2023) — Scienter under the FCA is subjective: if a defendant had a reasonable (even if wrong) understanding of its legal obligations, it may not have acted "knowingly"; the question is what the defendant actually believed, not what a court later determines was the objectively correct interpretation

Key Mechanics

The False Claims Act (31 U.S.C. §§ 3729–3733) imposes civil liability on any person who knowingly submits a false claim for payment to the federal government, knowingly uses a false record to get a false claim paid, or conspires to defraud the government. "Knowingly" includes actual knowledge, deliberate ignorance, and reckless disregard — the government does not need to prove intent to defraud. Damages are treble the government's loss plus a civil penalty ($13,946–$27,894 per violation as of 2024, adjusted periodically). The law's most consequential feature is the qui tam provision: private citizens ("relators") with knowledge of fraud can file suit on behalf of the government, and if the government recovers, the relator receives 15–30% of the proceeds as a reward. DOJ may intervene in qui tam suits (joining and taking over prosecution) or decline, in which case the relator may proceed on their own. Health care fraud — false billing to Medicare, Medicaid, and other federal programs — accounts for the vast majority of FCA recoveries.

How It Works

History: The Lincoln Law and the 1986 Revolution

Congress enacted the first False Claims Act in 1863 as a response to massive contractor fraud during the Civil War — suppliers were selling the Union Army horses that had died, sand in place of sugar, and defective munitions. The 1863 Act included a qui tam provision, allowing private parties to file suit and share in the recovery. But the Act was weakened over time, and by the early twentieth century its qui tam provisions were rarely used.

The 1986 amendments to the FCA transformed it from a largely dormant statute into the government's most powerful fraud-recovery tool. Congress strengthened the qui tam provisions, raised the relator's share from 10 to 15–30 percent, added anti-retaliation protections for whistleblowers, and established the "knowing" standard (including deliberate ignorance and reckless disregard) rather than requiring proof of specific intent to defraud. The 1986 amendments made qui tam suits economically attractive enough that relators and their attorneys began filing them in large numbers.

The results have been striking. The FCA has recovered over $75 billion since the 1986 amendments, with health care fraud accounting for the majority. A relator who identifies a major Medicare billing fraud scheme can recover tens of millions of dollars in qui tam shares; this financial incentive has created a thriving qui tam bar of specialized attorneys who actively recruit whistleblowers.

What Counts as a "False Claim"

The FCA covers a broad range of fraudulent conduct: submitting invoices for goods or services not provided, overbilling for services rendered, billing for medically unnecessary procedures, falsely certifying compliance with regulatory requirements, paying kickbacks to physicians for referrals (which then renders subsequent Medicare claims false), and violating the terms of government contracts. The key elements are: (1) a claim for payment; (2) that is false or fraudulent; (3) submitted with the requisite scienter (knowing, deliberately ignorant, or recklessly disregardful of the truth); (4) to the federal government (or a contractor, grantee, or entity receiving federal funds).

Universal Health Services v. United States ex rel. Escobar (2016) established the "implied false certification" doctrine: when a defendant submits a claim to the government, it impliedly certifies compliance with all conditions that are material to the government's payment decision. A hospital that bills Medicare for services rendered by unlicensed practitioners has made a false claim not by lying about whether services were rendered but by impliedly claiming compliance with licensing requirements that are material to Medicare coverage. However, the Court also demanded rigorous application of the materiality element — only conditions whose violation would affect the government's payment decision are "material." Courts have struggled to apply Escobar's materiality standard consistently; the question of whether the government would actually withhold payment for a particular regulatory violation if it knew about it is often hard to assess.

United States ex rel. Supervalu Inc. v. United States (2023) addressed the scienter requirement and held it is subjective: the question is not whether the defendant's interpretation of the law was objectively reasonable, but whether the defendant actually believed it was complying with its legal obligations. This significantly limits FCA liability in areas of genuine legal ambiguity — a defendant who adopted a reasonable (but ultimately incorrect) interpretation of a regulation may lack the requisite "knowing" state of mind, even if the interpretation was later found wrong by a court.

Qui Tam Mechanics

A relator who knows of FCA violations files a sealed complaint under 31 U.S.C. § 3730(b). The complaint is served on the government but not on the defendant; the relator cannot tell the defendant that a qui tam suit exists. The government then has 60 days — often extended substantially, sometimes for years — to investigate the allegations and decide whether to intervene.

If the government intervenes, it takes primary control of the litigation. The relator receives 15–25 percent of the recovery, with higher shares for relators who substantially contributed to the prosecution. The government can settle the case over the relator's objection (subject to court approval), though Polansky (2023) clarified that the government must formally intervene before moving to dismiss.

If the government declines to intervene, the relator may proceed independently with the suit. The relator receives 25–30 percent of any recovery — a higher share reflecting the risk of proceeding without government resources. Declined cases are much harder to win and are resource-intensive; many relator-attorneys will not accept cases the government has declined.

The public disclosure bar prevents qui tam suits based entirely on information already in the public domain — government reports, audits, congressional hearings, news articles — unless the relator is an "original source." This prevents opportunistic suits by relators who simply read publicly available disclosures of fraud and claim a share of any recovery. An original source must have independent knowledge that materially adds to the public disclosure, or must have voluntarily disclosed the information to the government before the public disclosure.

The first-to-file rule bars subsequent qui tam suits based on the same underlying fraud once one relator has filed. This discourages multiple relators from filing competing suits about the same conduct; the first relator gets priority.

Anti-Retaliation Protections

The FCA protects employees who report FCA violations or who assist in FCA investigations. An employee who is fired, demoted, suspended, threatened, or harassed because of protected FCA activity is entitled to reinstatement, double back pay (with interest), and compensation for any special damages including litigation costs and attorney fees. Courts have interpreted FCA-protected activity broadly to include internal reporting of potential FCA violations, not just formal qui tam filings.

Health Care Fraud: The FCA's Primary Domain

Health care fraud — particularly Medicare and Medicaid fraud — is the FCA's largest enforcement area. Common health care fraud schemes include billing for services not rendered, billing for higher-cost services than provided (upcoding), medically unnecessary services, kickbacks to physicians for referrals (which render Medicare claims false under the Anti-Kickback Statute), and inflated pricing for pharmaceutical products. The federal government and relators have recovered tens of billions of dollars from hospital systems, pharmaceutical companies, medical device manufacturers, and individual practitioners under the FCA.

How It Affects You

If you are a government contractor or health care provider: Any false statement or material omission in a claim submitted to the federal government, or in a document submitted to obtain a federal contract or grant, can trigger FCA liability. The penalties — approximately $14,308–$28,619 per claim (2025 inflation-adjusted; updated annually) plus treble damages — accumulate rapidly in high-volume billing situations (e.g., thousands of Medicare claims per year). Implement robust compliance programs: verify billing accuracy, train staff on regulatory requirements, and create internal channels for employees to report potential violations. The Escobar materiality standard requires that you identify which regulatory conditions are truly material to federal payment decisions. After Supervalu, documented good-faith legal analysis of ambiguous regulatory requirements supports an argument that any error was not "knowing."

If you are considering filing a qui tam action: The financial incentive is real — relators receive 15–30 percent of the government's recovery, which can be enormous in large fraud cases. But qui tam suits require an attorney with specialized expertise; the procedural requirements (sealed filing, service on the government, intervention decision) are strict. The public disclosure bar means you must have inside knowledge beyond what is publicly available. The first-to-file rule means you should act promptly if you know of fraud that others might also be aware of. Anti-retaliation protections cover you if your employer retaliates for reporting fraud, but retaliation claims are separate from the underlying qui tam suit and require their own proof.

If you are an employee aware of potential fraud: The FCA's anti-retaliation provisions protect you for reporting potential violations internally or assisting in a government investigation — you don't need to file a qui tam suit to receive protection. Document your concerns in writing; create a record of when and to whom you reported. If you are discharged after reporting, consult an employment attorney immediately about both FCA retaliation claims and any applicable state whistleblower protections. FCA protection applies to internal complaints, not just formal legal filings.

If you are a defense attorney representing a defendant in an FCA case: After Supervalu (2023), the subjective scienter standard opens significant avenues for defense. Was the legal obligation ambiguous? Did the defendant have a reasonable basis for its interpretation, even if ultimately incorrect? Build a record of the defendant's actual understanding of its legal obligations at the time of the allegedly false claims. The Escobar materiality standard also provides a defense: if the government continued to pay claims after learning of the alleged violation (as often happens in large-scale investigations), this is strong evidence that the condition was not "material" to the government's payment decision.

State Variations

Thirty-one states and the District of Columbia have enacted their own state False Claims Acts, modeled on the federal statute and covering fraud against state Medicaid programs and other state government expenditures. Many state FCAs include qui tam provisions with relator shares comparable to the federal Act. The federal government provides financial incentives for states to enact qualifying FCAs (states with strong FCAs receive a larger share of federal Medicaid recoveries). State FCAs vary in:

• Coverage: Whether they cover only Medicaid fraud or all state government expenditures
• Relator share: Most states track the federal 15–30 percent range
• Public disclosure bar: State versions may be broader or narrower than the federal bar
• Scienter: Some states have lower scienter requirements, making claims easier to bring
• Immunity: Some states explicitly allow FCA suits against state government contractors; others limit suit to non-governmental defendants

California's False Claims Act is among the most plaintiff-friendly, with a lower materiality threshold and broader coverage. The New York False Claims Act has generated significant recoveries in cases involving New York Medicaid fraud.

Pending Legislation

• False Claims Amendments Act: Periodic congressional attention to the FCA's scope — proposals to address the Escobar materiality standard (some proposals would lower the bar for plaintiffs; others would raise it), to codify or override Supervalu's subjective scienter standard, and to strengthen anti-retaliation protections for relators
• Digital Health Care Fraud Provisions: Growing legislative attention to AI-assisted billing fraud and telehealth fraud schemes; FCA applicability to automated billing systems is an emerging enforcement priority

Recent Developments

• 2023 — Supervalu: The Supreme Court held unanimously that FCA scienter is subjective — if the defendant held a reasonable but incorrect legal interpretation, it may not have acted "knowingly"; this significantly limits FCA liability in areas of legal ambiguity and creates a meaningful subjective good-faith defense.
• 2023 — Polansky: The Supreme Court resolved a circuit split and held that the government may seek dismissal of a declined qui tam case if it first intervenes for that purpose; relators do not have absolute right to proceed despite government opposition.
• 2024–2026 — Health care enforcement surge: DOJ and HHS-OIG have prioritized FCA enforcement against telehealth fraud, COVID-19 relief fund fraud, and pharmaceutical kickback schemes; recoveries have exceeded $2 billion annually in recent years.
• 2024–2026 — AI and automated billing: Enforcement attention is turning to AI-assisted upcoding and automated billing systems that generate false claims at scale; FCA liability for automated systems — including the scienter question for algorithmic billing — is an emerging frontier.